Results 61 to 70 of about 457,473 (371)

Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma [PDF]

open access: yes, 2015
The prevalence of global obesity is increasing. Obesity is associated with general cancer-related morbidity and mortality and is a known risk factor for development of specific cancers.
Alfraidi, Albandri   +5 more
core   +2 more sources

Targeting STAT3 in Cancer with Nucleotide Therapeutics. [PDF]

open access: yes, 2019
Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an "undruggable" target for ...
Grandis, Jennifer R   +3 more
core   +2 more sources

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

open access: yesHepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou   +15 more
wiley   +1 more source

JAK2 (janus kinase 2) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

open access: yesHepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu   +20 more
wiley   +1 more source

Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1 [PDF]

open access: yes, 2015
Suppressor of cytokine signalling 3 (SOCS3) is a potent inhibitor of pro-inflammatory pathways involved in atherogenesis and the development of neo-intimal hyperplasia (NIH), which contributes to the in-stent re-stenosis responsible for the failure of ...
Palmer, Timothy P., Yarwood, Stephen J.
core   +1 more source

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

open access: yesHepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong   +9 more
wiley   +1 more source

The helicase HAGE prevents interferon-a-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1 [PDF]

open access: yes, 2014
The tumour suppressor PML (promyelocytic leukaemia protein) regulates several cellular pathways involving cell growth, apoptosis, differentiation and senescence.
A Carracedo   +33 more
core   +1 more source

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

open access: yesCancer, 2019
Canonical Janus kinase 2 (JAK2) V617F and exon 12 mutations in myeloid neoplasms are well described. There are limited reports of other JAK2 variants of potential clinical relevance.
C. Benton   +17 more
semanticscholar   +1 more source

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening

open access: yesSLAS Discovery, 2023
JAK2 transmits signals of several important cytokines, such as growth hormone and erythropoietin. The interest toward the therapeutic targeting of JAK2 was boosted in 2005, when the somatic JAK2 V617F mutation, responsible for the majority of ...
Angelika Pölläniemi   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy